



**Strategy and Sustainability Division  
MINISTRY FOR HEALTH, THE ELDERLY AND COMMUNITY CARE**

**DH CIRCULAR No. 249/2010**

**DH 3838/2010**

3<sup>rd</sup> November 2010

**Attention all** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Re: New medicine on the Government Formulary List: Rasigiline 1mg tablets**

Rasagiline has been recommended by the Government Formulary List Advisory Committee and approved by the Superintendent of Public Health for the introduction into the Government Formulary List. The Consultant Neurologist can prescribe Rasagiline for the treatment of idiopathic Parkinson's disease (PD) as monotherapy or as adjunct therapy in patients with end of dose fluctuations. Rasigiline is protocol-regulated and the protocol number is 268 (attached).

Rasagiline 1mg tablets have been procured through GHPS and are now available for use as per protocol.

Thank you

For your attention, please

Dr Natasha Azzopardi Muscat  
Director General

## **Rasagiline 1mg tablets**

**Prescriber Criteria:** Consultant Neurologist

**Clinical Indications:**

Treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations

**Conditions qualifying patient for drug:**

Parkinson's disease

**Investigations prior to starting treatment:**

Liver function tests

**Treatment evaluation/ Clinical parameters:**

Less PD symptoms

**Objective indicators of efficacy:**

An increase in extracellular levels of dopamine in the striatum

**Frequency of review:**

Yearly